Document is current
Any future updates will be listed below
-
Authors
Wang, Xiaoping
Zhao, Li
Song, Xingzhi
Wu, Xiaogang
Krishnamurthy, Savitri
Semba, Takashi
Shao, Shan
Knafl, Mark https://orcid.org/0000-0002-3953-2173
Coffer, Larry W. II
Alexander, Angela https://orcid.org/0000-0002-6649-7991
Vines, Anita
Bopparaju, Swetha
Woodward, Wendy A.
Chu, Randy
Zhang, Jianhua
Yam, Clinton
Loo, Lenora W. M.
Nasrazadani, Azadeh
Huong, Le-Petross
Woodman, Scott E.
Futreal, Andrew https://orcid.org/0000-0001-8663-2671
,
Rawi, Ahmed N. Al
Arrechedera, Claudio A.
Ayers, Kimberly S.
Bedoya, Claudia Alvarez
Burton, Elizabeth
Chon, Connie A.
Chu, Randy Aaron
Crosby, Shadarra D.
Do, Jonathan
Lima, Cibelle Freitas Pinto
Fu, Szu-Chin
Futreal, Andy
Garcia, Ana L.
Garcia-Prieto, Celia
Gite, Swati
Gumbs, Curtis
Hargraves, Kristin J.
He, Meng
Horombe, Chacha
Ibarguen, Heladio P.
Jackson, Stacy
Jacob, Jeena
Jiang, Mei
Khanduri, Isha
Kinyua, Walter K.
Lang, Wenhua
Little, Latasha D.
Lu, Wei
Mallampati, Saradhi
Mendoza, Mary Gertrude T.
Meric-Bernstam, Funda
Mohammad, Mohammad Moustaf
Piubelli, Mario Luiz Marques
Prabhakaran, Sabitha
Shaw, Kenna R.
Song, Ping
Song, Xiaofei
Subramanya, Sandesh
Sun, Baohua
Virani, Shumaila
Wang, Wanlin
Wistuba, Ignacio
Xu, Mingchu
Zhang, Qingxiu C.
Zhang, Shanyu
Tripathy, Debu https://orcid.org/0000-0002-5711-2404
Ueno, Naoto T. https://orcid.org/0000-0002-0166-7275
- License Information
-
More Information
Article History
Received: 4 May 2024
Accepted: 1 October 2024
First Online: 18 November 2024
Competing interests
: C.Y. has received research support (to the institution) from Amgen, Merck, Genentech, and GSK. N.T.U. holds consulting roles with the following companies: AstraZeneca Pharmaceuticals LP (USA and UK), Bayer AG, Bristol Myers Squibb Company, Carna Biosciences, Inc., CytoDyn Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Genentech, Inc., Genomic Health, Inc., Gilead Sciences, Inc., Lavender Health, OncoCyte Corporation, Pear Bio, Peptilogics, Inc., Pfizer Inc., Phoenix Molecular Designs, Preferred Medicine, Carisma Therapeutics, Inc., Sysmex Corporation, Takeda Pharmaceutical Company Limited (Japan), and Unitech Medical, Inc. N.T.U. holds consulting roles with the following companies: AstraZeneca Pharmaceuticals LP (USA and UK), Bayer AG, Bristol Myers Squibb Company, Carna Biosciences, Inc., CytoDyn Inc., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Genentech, Inc., Genomic Health, Inc., Gilead Sciences, Inc., Lavender Health, OncoCyte Corporation, Pear Bio, Peptilogics, Inc., Pfizer Inc., Phoenix Molecular Designs, Preferred Medicine, Carisma Therapeutics, Inc., Sysmex Corporation, Takeda Pharmaceutical Company Limited (Japan), and Unitech Medical, Inc. N.T.U. has ownership of stock: Pear Bio and Phoenix Molecular Designs. N.T.U. holds speaker or preceptorship roles with the following companies: Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Pfizer Inc., AstraZeneca Pharmaceuticals LP, Total Health Conferencing, and Eli Lilly and Company. N.T.U. has research agreements in place with the following companies: AnHeart Therapeutics Inc., Eisai Co., Ltd., Gilead Sciences, Inc., Phoenix Molecular Designs, Daiichi Sankyo, Inc., Puma Biotechnology, Inc., Merck Co., Oncolys BioPharma Inc., OBI Pharma Inc., ChemDiv, Inc., Tolero Pharmaceuticals, Inc., and VITRAC Therapeutics, LLC. All other authors have no relevant conflict of interest disclosures.
